Pharmacy Guide
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Pharmacy Guide
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Simalvia 60 mg/300 mg Capsule
⚠ This medicine appears to have been discontinued
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Alverine citrate, Simeticone may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
What it is and what it is used for
for SimAlvia contains two active ingredients:
- alverine that belongs to a class of drugs called musculotropic antispasmodics,
- and simeticone that belongs to a class of medicines called antiflatulents, This medicine reduces the muscle contractions of the gut and flatulence (gas). It is used to relieve pain associated with contractions (spasms) of the intestine and bloating. This medicine is for adults only.
What you need to know before you take it
e SimAlvia, soft capsules Do not take SimAlvia
- if you are allergic to alverine citrate or simeticone or any of the other ingredients of this medicine (listed in section 6).
- if you have had any unwanted effects after taking this medicine.
- if you are allergic to peanut or soya, because SimAlvia, soft capsules contains soya lecithin.
- if you have been told by your doctor that you have paralytic ileus.
- if you are suffering from severe constipation.
- if you are pregnant.
- if you are breastfeeding.
Consult your doctor if you have developed new symptoms, or if your symptoms worsen, or if they do not improve after 2-week treatment. Other medicines and SimAlvia Tell your doctor or pharmacist if you are taking- have recently taken or might take any other medicines, including medicines obtained without a prescription Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. The safety of alverine citrate for use during pregnancy and breast-feeding has not been established. Hence, it should be taken only if your doctor advises to do so. SimAlvia contains soya lecithin If you are allergic to peanut or soya, do not use this medicinal product.
How to take it
SimAlvia, soft capsules Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. Dosage The recommended dose is 1 capsule 2 or 3 times a day. Method of administration This medicine is to be taken orally at the beginning of meals. Swallow the capsule with a glass of water. If you take more SimAlvia than you should Dizziness has been reported after taking more than the recommended dose. Consult your doctor or pharmacist immediately. If you forget to take SimAlvia Do not take a double dose to make up for a forgotten capsule. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
How to store it
SimAlvia, soft capsules Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton.The expiry date refers to the last day of that month. Store below 25°C. Keep in outer carton in order to protect from light. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment. B001553 7180814
Contents of the pack and other information
Like all medicines, this medicine can cause side effects, although not everybody gets them.
What SimAlvia contains
- The active substances for one soft capsule are: alverine citrate (60 mg) and simeticone (300 mg).
- The components of the capsule shell are: gelatin, glycerol and titanium dioxide and soya lecithin and fractionated coconut oil are used as external lubricants.
If you experience any of the following side effects, stop taking the treatment and contact a doctor immediately:
- Signs of a severe allergic reaction, particularly swelling of the face, lips, mouth, tongue and/or throat, that can cause difficulties in breathing or swallowing, skin rash, itching, severe dizziness with increased heart rate and copious sweating (severe allergic reaction considered to be very rare, in other words affecting less than 1 person in 10,000).
- Signs suggestive of a liver dysfunction. Symptoms may include yellowing of the skin or the white of the eyes, dark colour of urine, paler stools, loss of appetite, unexplained and persistent nausea, unusual tiredness or vomiting (effect on the liver considered to be very rare, in other words affecting less than 1 person in 10,000). The following other side effects have been reported with unknown frequency (the available information does not allow to evaluate the frequency):
- Skin rash,
- Urticaria (swollen pale or red skin wheals that may itch, burn or sting),
- Itching,
- Dizziness,
- Headaches,
- Nausea (feeling sick),
- Increased blood levels of liver enzymes (transaminases, alkaline phosphatase) and bilirubin (see section 2). Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
What SimAlvia looks like and contents of the pack This medicine is in the form of whitish and oblong soft capsule. Each box contains 10, 20, 30, 40, 60 or 90 soft capsules in blisters. Not all pack sizes may be marketed. Marketing Authorisation Holder Laboratoires GALENIQUES VERNIN 20, rue Louis-Charles Vernin 77190 Dammarie-les-Lys – FRANCE Manufacturer Creapharm Industry 29 rue Léon Faucher 51100 Reims France This medicine is authorised in the Member States of the European Economic Area and in the United Kingdom (Northern Ireland) under the following names: Belgium: Simalviane Ireland: SimAlvia United Kingdom (Northern Ireland): SimAlvia Distributed in the UK by: MAYOLY UK Limited This leaflet was last revised in 10/2025
By reporting side effects you can help provide more information on the safety of this medicine.
Frequently asked questions about Simalvia 60 mg/300 mg Capsule
How do I take Simalvia 60 mg/300 mg Capsule?
Simalvia 60 mg/300 mg Capsule comes as capsule containing 60mg / 300mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
What is the active substance in Simalvia 60 mg/300 mg Capsule?
The active substance in Simalvia 60 mg/300 mg Capsule is alverine citrate, simeticone.
Where does this information come from?
This leaflet reproduces the patient information leaflet approved for Simalvia 60 mg/300 mg Capsule, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Can I get Simalvia 60 mg/300 mg Capsule without a prescription?
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
About this leaflet
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
- Source: electronic medicines compendium (emc), Datapharm
- Active substance: alverine citrate, simeticone
- Official document: view the original leaflet on emc →
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
4.1. Therapeutic indications
Relief of abdominal pain in irritable bowel syndrome.
SimAlvia, soft capsule is indicated in adults only.
4.2. Posology and method of administration
Posology
Paediatric population
The safety and efficacy of SimAlvia, soft capsules in children under 18 years of age have not been established.
Method of administration
For oral administration
Adults (including the elderly
1 soft capsule two to three times daily at the beginning of meals.
4.3. Contraindications
Paralytic ileus
Intestinal obstruction
Use in pregnancy and lactation
History of allergic reaction or intolerance to alverine or to any of the excipients
Hypersensitivity to peanut or soya.
4.4. Special warnings and precautions for use
Other causes of gastro intestinal pathology should be outruled, and patients not improving after 2 weeks of treatment should be reviewed by physician.
Liver function:
Elevations in ALT (Alanine Aminotransferase) and AST (Aspartate Aminotransferase) > twice the upper limit of normal (ULN) have been reported in patients receiving treatment with alverine/simeticone. These elevations may be associated with a concomitant elevation in total serum bilirubin (see section 4.8). In case of an elevation in hepatic aminotransferases > 3 times the ULN and/or in the case of jaundice, treatment with alverine/simeticone should be discontinued.
Patients should be warned to report immediately any signs and symptoms of unexplained persistent nausea, decreased appetite, fatigue, vomiting, right upper abdominal pain, or jaundice, dark urine or pale faeces. Patients with these symptoms should discontinue taking SimAlvia and the patient's hepatic function should be immediately evaluated.
4.5. Interaction with other medicinal products and other forms of interaction
None known.
4.6. Fertility, pregnancy and lactation
Pregnancy
Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).
A moderate amount of data on pregnant women indicate no malformative or feto/ neonatal toxicity of alverine citrate. There are no data from the use of simeticone or the combination in pregnant women.
As a precautionary measure, it is preferable to avoid the use of SimAlvia, soft capsules during pregnancy.
Breastfeeding
It is unknown whether alverine citrate or simeticone and their metabolites are excreted in human milk. This medicinal product should be avoided during breastfeeding.
Fertility
There are no data on the effects of alverine citrate or simeticone on human fertility.
4.7. Effects on ability to drive and use machines
Alverine/simeticone has a minor influence on the ability to drive and use machines. Adverse effects such as vertigo have been reported in some patients (see sections 4.8 and 4.9). These types of disorders may affect the ability to drive and use machines.
4.8. Undesirable effects
The side effects listed below have been reported at frequencies corresponding to: very common (≥ 1/10), common (≥ 1/100 to <1/10), uncommon (≥ 1/1,000 to <1/100), rare (≥ 1/10,000 to <1/1,000), very rare (<1/10,000) and not known frequency (cannot be estimated on the basis of the available data).
Due to the presence of alverine:
Hepatobiliary disorders
Very rare
Cytolytic hepatitis (see section 4.4).
Investigation
Not known
Elevated transaminases, alkaline phosphatase, and bilirubin.
Skin and subcutaneous tissue disorders:
Not known
Angioedema, skin rash, urticaria, and pruritus.
Immune system disorders
Very rare
Anaphylactic type reactions, and anaphylactic shock.
Ear and labyrinth disorders
Not known
Vertigo.
Nervous system disorders
Not known
Headache.
Gastrointestinal disorders
Not known
Nausea.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the MHRA Yellow Card Scheme
Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
4.9. Overdose
Cases of vertigo have been reported when a higher-than-recommended dosage is taken.
🇵🇱 Known in Poland as
Medicines sold in Poland with the same active substance: W Polsce znany jako
⚠ Same active substance, but a different pharmaceutical form (for example a gel instead of a tablet). Not interchangeable — ask a pharmacist.
- MeteospasmylAlverini citras + Simeticonum
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
💬 Ask about this leaflet
Ask anything about Simalvia 60 mg/300 mg Capsule. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.